Thyroid Eye Disease

Less than 5% of adults with thyroid eye disease who completed a full course of teprotumumab therapy required an additional course of the agent, according to a presenter at the American Thyroid Association annual meeting.

CHICAGO — Commercial insurer payments for teprotumumab vary dramatically, with cost influencing access to care and cost-effectiveness, according to a study presented at the ASOPRS Fall Scientific Symposium.

CHICAGO — New target therapies and improvements in surgical techniques are leading to a change in the expectations and outcomes of patients with thyroid eye disease.

CHICAGO — Patients who received Tepezza to treat thyroid eye disease showed improved extraocular muscle size that correlated to improved diplopia and motility, according to a presenter here.

CHICAGO — Biologics are a game changer for the treatment of thyroid eye disease, according to one speaker at the American Academy of Ophthalmology meeting.

CHICAGO — Pretreatment evaluation of fat-to-muscle ratio in thyroid eye disease will allow for the best treatment choice, a presenter here said.

CHICAGO — Management of thyroid eye disease requires a carefully planned, personalized approach, according to Michael Kazim, MD, speaking at the American Academy of Ophthalmology meeting.

CHICAGO — Since its approval in 2020, Tepezza has become a go-to treatment for moderate to severe thyroid eye disease, unseating orbital decompression as the most used treatment, according to a presenter here.

CHICAGO — Ophthalmologists should monitor patients with thyroid eye disease when they receive their COVID-19 vaccinations, according to a small case study presented at the ASOPRS Fall Scientific Symposium.

MONTEREY, Calif. — In this Healio Video Perspective from the Women in Ophthalmology Summer Symposium, Tanya Khan, MD, discusses the importance of considering thyroid eye disease when treating patients with nonspecific visual and orbital complaints.